Largest pharmaceuticals by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 61 pharmaceuticals ranked by net assets, at CHF 72.8B, ahead of Johnson & Johnson (CHF 68.7B) and Sanofi (CHF 66.7B). Figures as of 18 Nov 2026, 14:23 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 61
- First
- PfizerCHF 72.8B
- Median
- CHF 739.8M
- Combined market value
- CHF 4.35T
- Countries
- 10
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | CHF 72.8B | CHF 136.7B | CHF 23.98 | 1.35% down | 14% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | CHF 68.7B | CHF 565.2B | CHF 234.78 | 1.36% down | 38% up | ||
| 3 | SanofiSNY · Health Care | CHF 66.7B | CHF 96.1B | CHF 40.04 | 1.78% down | 4% down | ||
| 4 | Merck & CoMRK · Health Care | CHF 44.3B | CHF 297.7B | CHF 120.78 | 0.75% down | 51% up | ||
| 5 | Abbott LaboratoriesABT · Health Care | CHF 43.9B | CHF 152.8B | CHF 88.21 | 2.55% down | 17% down | ||
| 6 | AstraZenecaAZN · Health Care | CHF 41B | CHF 238.1B | CHF 153.55 | 0.95% down | 2% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | CHF 39.2B | CHF 58.2B | CHF 18.23 | 0.23% up | 54% up | ||
| 8 | NovartisNVS · Health Care | CHF 38.9B | CHF 253.2B | CHF 134.05 | 0.67% down | 25% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | CHF 26.3B | CHF 83.5B | CHF 806.84 | 0.56% up | 36% up | ||
| 10 | Novo NordiskNVO · Health Care | CHF 24.3B | CHF 151.1B | CHF 34.29 | 2.16% down | 17% down | ||
| 11 | Eli LillyLLY · Health Care | CHF 22.4B | CHF 1.06T | CHF 1,192.49 | 1.13% down | 35% up | ||
| 12 | GSKGSK · Health Care | CHF 18.3B | CHF 83.1B | CHF 41.48 | 2.32% down | 6% up | ||
| 13 | Vertex PharmaceuticalsVRTX · Health Care | CHF 15.7B | CHF 114.1B | CHF 450.02 | 0.67% down | 27% up | ||
| 14 | Bristol-Myers SquibbBMY · Health Care | CHF 15.6B | CHF 105.6B | CHF 51.68 | 2.51% down | 34% up | ||
| 15 | ViatrisVTRS · Health Care | CHF 12.4B | CHF 19.8B | CHF 17.23 | 1.40% down | 96% up | ||
| 16 | Royalty PharmaRPRX · Health Care | CHF 8.2B | CHF 33.3B | CHF 57.86 | 0.23% up | 78% up | ||
| 17 | Teva Pharmaceutical IndustriesTEVA · Health Care | CHF 6.7B | CHF 41.9B | CHF 35.90 | 0.12% up | 74% up | ||
| 18 | United TherapeuticsUTHR · Health Care | CHF 6B | CHF 21B | CHF 492.06 | 0.64% down | 23% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | CHF 5.5B | CHF 10.9B | CHF 21.78 | 2.12% down | 20% up | ||
| 20 | BioMarin PharmaceuticalBMRN · Health Care | CHF 5.1B | CHF 9.5B | CHF 49.29 | 0.90% up | 11% up | ||
| 21 | GrifolsGRFS · Health Care | CHF 4.9B | CHF 4.9B | CHF 7.27 | 1.15% down | 1% up | ||
| 22 | GenmabGMAB · Health Care | CHF 4.9B | CHF 27B | CHF 43.77 | 0.76% up | 70% up | ||
| 23 | Roivant SciencesROIV · Health Care | CHF 3.8B | CHF 23.6B | CHF 32.61 | 0.26% up | 90% up | ||
| 24 | BeOne MedicinesONC · Health Care | CHF 3.7B | CHF 39.8B | CHF 348.14 | 0.48% up | 17% up | ||
| 25 | Jazz PharmaceuticalsJAZZ · Health Care | CHF 3.6B | CHF 13B | CHF 202.78 | 0.39% up | 37% up | ||
| 26 | Dr. Reddy's LaboratoriesRDY · Health Care | CHF 3.4B | CHF 10.4B | CHF 12.46 | 0.61% up | 5% up | ||
| 27 | ZoetisZTS · Health Care | CHF 2.8B | CHF 28.6B | CHF 70.33 | 1.08% down | 29% down | ||
| 28 | AlkermesALKS · Health Care | CHF 1.5B | CHF 6.4B | CHF 38.29 | 2.32% down | 58% up | ||
| 29 | Ligand PharmaceuticalsLGND · Health Care | CHF 856.9M | CHF 5B | CHF 247.51 | 2.62% down | 43% up | ||
| 30 | Legend BiotechLEGN · Health Care | CHF 844.2M | CHF 2.6B | CHF 13.57 | 0.75% up | 42% down | ||
| 31 | Praxis Precision MedicinesPRAX · Health Care | CHF 739.8M | CHF 7.2B | CHF 256.99 | 1.68% down | 61% up | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | CHF 664.8M | CHF 17.7B | CHF 131.84 | 2.02% down | 66% down | ||
| 33 | Belite BioBLTE · Health Care | CHF 649.1M | CHF 5.4B | CHF 132.87 | 2.98% down | 31% up | ||
| 34 | InsmedINSM · Health Care | CHF 622.5M | CHF 22.5B | CHF 102.66 | 0.83% down | 40% down | ||
| 35 | Spyre TherapeuticsSYRE · Health Care | CHF 602.5M | CHF 7.5B | CHF 79.03 | 5.60% down | 286% up | ||
| 36 | Summit TherapeuticsSMMT · Health Care | CHF 555M | CHF 7.2B | CHF 8.99 | 9.73% down | 36% down | ||
| 37 | TG TherapeuticsTGTX · Health Care | CHF 545.9M | CHF 8B | CHF 52.83 | 0.08% down | 107% up | ||
| 38 | Corcept TherapeuticsCORT · Health Care | CHF 545.7M | CHF 6.5B | CHF 59.03 | 1.23% up | 8% down | ||
| 39 | Cogent BiosciencesCOGT · Health Care | CHF 536.1M | CHF 4.1B | CHF 23.46 | 1.49% up | 20% down | ||
| 40 | Protagonist TherapeuticsPTGX · Health Care | CHF 517.8M | CHF 6.9B | CHF 105.02 | 0.13% down | 46% up | ||
| 41 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 507.7M | CHF 8.3B | CHF 355.49 | 0.46% down | 24% down | ||
| 42 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | CHF 478.2M | CHF 6.3B | CHF 80.12 | 0.93% up | 126% up | ||
| 43 | Edgewise TherapeuticsEWTX · Health Care | CHF 440M | CHF 3.9B | CHF 35.42 | 3.75% down | 88% up | ||
| 44 | ABIVAXABVX · Health Care | CHF 425.5M | CHF 6.1B | CHF 69.16 | 1.81% down | 27% down | ||
| 45 | Dianthus TherapeuticsDNTH · Health Care | CHF 415.7M | CHF 4.1B | CHF 73.27 | 2.87% down | 113% up | ||
| 46 | Ionis PharmaceuticalsIONS · Health Care | CHF 412M | CHF 3.8B | CHF 22.71 | 3.75% down | 64% down | ||
| 47 | Oruka TherapeuticsORKA · Health Care | CHF 397.6M | CHF 5.5B | CHF 81.14 | 2.94% down | 241% up | ||
| 48 | Arrowhead PharmaceuticalsARWR · Health Care | CHF 392.6M | CHF 5.1B | CHF 36.22 | 2.76% down | 10% up | ||
| 49 | Definium TherapeuticsDFTX · Health Care | CHF 280M | CHF 3.4B | CHF 24.75 | 2.59% down | 169% up | ||
| 50 | ErascaERAS · Health Care | CHF 273.9M | CHF 4.1B | CHF 11.70 | 8.07% down | 403% up | ||
| 51 | Mirum PharmaceuticalsMIRM · Health Care | CHF 265.1M | CHF 5.1B | CHF 77.46 | 0.40% up | 31% up | ||
| 52 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 117.2M | CHF 6.8B | CHF 98.23 | 8.49% up | 13% up | ||
| 53 | Travere TherapeuticsTVTX · Health Care | CHF 96.7M | CHF 4.1B | CHF 43.05 | 2.82% up | 44% up | ||
| 54 | Axsome TherapeuticsAXSM · Health Care | CHF 74.4M | CHF 6B | CHF 114.53 | 0.77% down | 7% down | ||
| 55 | Amneal PharmaceuticalsAMRX · Health Care | -CHF 59.6M | CHF 6.2B | CHF 17.79 | 0.52% down | 83% up | ||
| 56 | VeradermicsMANE · Health Care | -CHF 101.9M | CHF 4.5B | CHF 105.84 | 1.88% down | 233% up | ||
| 57 | Ascendis PharmaASND · Health Care | -CHF 152.2M | CHF 15B | CHF 228.46 | 0.20% down | 28% up | ||
| 58 | PTC TherapeuticsPTCT · Health Care | -CHF 173M | CHF 4.2B | CHF 50.85 | 1.00% down | 20% down | ||
| 59 | CytokineticsCYTK · Health Care | -CHF 555.7M | CHF 6.1B | CHF 43.51 | 2.86% down | 20% down | ||
| 60 | BridgeBio PharmaBBIO · Health Care | -CHF 1.8B | CHF 12.6B | CHF 64.70 | 0.72% down | 17% up | ||
| 61 | AbbVieABBV · Health Care | -CHF 2.8B | CHF 436B | CHF 246.68 | 0.59% down | 26% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8424 CHF).
Questions and answers
Which pharmaceuticals rank first by net assets?
Pfizer (CHF 72.8B), Johnson & Johnson (CHF 68.7B) and Sanofi (CHF 66.7B) are the top three of the 61 pharmaceuticals ranked by net assets as of 18 Nov 2026, 14:23 UTC.
How many pharmaceuticals are in this ranking?
61 are ranked by net assets.
What are these pharmaceuticals worth together?
The 61 pharmaceuticals ranked by net assets have a combined market value of CHF 4.35T as of 18 Nov 2026, 14:23 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.